Global Cobamamide for Injection Market Research Report 2022

Cobamamide is mainly used for megaloblastic anemia, malnutrition anemia, pregnancy anemia, polyneuritis, radiculopathy, trigeminal neuralgia, sciatica, nerve palsy, it can also be used for nutritional disorders, radiation, and drug-induced leukopenia.

Due to the COVID-19 pandemic, the global Cobamamide for Injection market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Cobamamide for Injection market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Cobamamide for Injection landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

0.5mg accounting for % of the Cobamamide for Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.

The global major manufacturers of Cobamamide for Injection include Haerbin Medisan, North China Pharmaceutical Group, Chongqing Yaoyou Pharmaceutical, Hainan Star Pharmaceutical, Hebei Zhitong Biopharmaceutical, Jiangsu Jiuxu Pharmaceutical and Jiuquan Dadeli pharmaceutical, etc. In terms of revenue, the global 3 largest players have a % market share of Cobamamide for Injection in 2021.

This report focuses on Cobamamide for Injection volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Cobamamide for Injection market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Global Cobamamide for Injection Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.


Segment by Type


0.5mg

1.0mg

1.5mg


Segment by Application


Hospital

Drug Store

Other

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE


By Company


Haerbin Medisan

North China Pharmaceutical Group

Chongqing Yaoyou Pharmaceutical

Hainan Star Pharmaceutical

Hebei Zhitong Biopharmaceutical

Jiangsu Jiuxu Pharmaceutical

Jiuquan Dadeli pharmaceutical

Frequently Asked Questions